Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials

The Lancet Gastroenterology and Hepatology

Volumn 3, Issue 4, 2018, Pages 231-241

  Scally, Benjamin ^a,b   Emberson, Jonathan R ^b   Spata, Enti ^b   Reith, Christina ^b   Davies, Kelly ^b   Halls, Heather ^b   Holland, Lisa ^b   Wilson, Kate ^b   Bhala, Neeraj ^c,d   Hawkey, Christopher ^e   Hochberg, Marc ^f   Hunt, Richard ^g   Laine, Loren ^h,i   Lanas, Angel ^j   Patrono, Carlo ^k   Baigent, Colin ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^j UNIVERSITY OF ZARAGOZA   (Spain)

^k CATHOLIC UNIVERSITY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; ANTIULCER AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BLOOD TRANSFUSION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DIGESTIVE SYSTEM PERFORATION; DUODENUM ULCER; ENDOSCOPY; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PEPTIC ULCER; PRIORITY JOURNAL; STOMACH ULCER; ULCER; UPPER GASTROINTESTINAL BLEEDING; COMPLICATION; PEPTIC ULCER BLEEDING; SECONDARY PREVENTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; HISTAMINE H2 ANTAGONISTS; HUMANS; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PROSTAGLANDINS, SYNTHETIC; PROTON PUMP INHIBITORS; SECONDARY PREVENTION;

EID: 85042874686     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(18)30037-2     Document Type: Article

References (30)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
2. WHO. Global health estimates 2014. http://www.who.int/healthinfo/global_burden_disease/estimates (accessed Jan 4, 2018).
3. Lanas, A, Chan, FKL, Peptic ulcer disease. Lancet 390 (2017), 613–624.
4. Soreide, K, Thorsen, K, Harrison, EM, et al. Perforated peptic ulcer. Lancet 386 (2015), 1288–1298.
5. Coxib and traditional NSAID Trialists' Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382 (2013), 769–779.
6. Rostom, A, Dube, C, Wells, G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev, 4, 2002 CD002296.
7. Leontiadis, GI, Sreedharan, A, Dorward, S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 11 (2007), 1–164.
8. Yuan, JQ, Tsoi, KK, Yang, M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther 43 (2016), 1262–1275.
9. Higgins, JPT, Green, S, Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March, 2011). http://handbook.cochrane.org/ (accessed Jan 4, 2018).
10. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer: worldwide evidence 1985–1990. 1990, Oxford University Press, Oxford.
11. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). http://www.prisma-statement.org/Default.aspx (accessed Jan 4, 2018).
12. Bhatt, DL, Cryer, BL, Contant, CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363 (2010), 1909–1917.
13. Li, L, Geraghty, OC, Mehta, Z, Rothwell, PM, Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 390 (2017), 490–499.
14. Vaduganathan, M, Cannon, CP, Cryer, BL, et al. Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT Trial. Am J Med 129 (2016), 1002–1005.
15. Vaduganathan, M, Bhatt, DL, Cryer, BL, et al. Proton-pump inhibitors reduce gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy. J Am Coll Cardiol 67 (2016), 1661–1671.
16. Sreedharan, A, Martin, J, Leontiadis, GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev, 7, 2010 CD005415.
17. Nuesch, E, Trelle, S, Reichenbach, S, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ, 341, 2010, c3515.
18. Hopewell, S, Loudon, K, Clarke, MJ, Oxman, AD, Dickersin, K, Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev, 1, 2009, MR000006.
19. Alshamsi, F, Belley-Cote, E, Cook, D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care, 20, 2016, 120.
20. Shih, CJ, Chen, YT, Ou, SM, Li, SY, Chen, TJ, Wang, SJ, Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol 177 (2014), 292–297.
21. Shah, NH, LePendu, P, Bauer-Mehren, A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One, 10, 2015, e0124653.
22. Fraser, LA, Leslie, WD, Targownik, LE, Papaioannou, A, Adachi, JD, CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int 24 (2013), 1161–1168.
23. Yu, EW, Bauer, SR, Bain, PA, Bauer, DC, Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124 (2011), 519–526.
24. Markovits, N, Loebstein, R, Halkin, H, et al. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol 54 (2014), 889–895.
25. Park, CH, Kim, EH, Roh, YH, Kim, HY, Lee, SK, The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One, 9, 2014, e112558.
26. Janarthanan, S, Ditah, I, Adler, DG, Ehrinpreis, MN, Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 107 (2012), 1001–1010.
27. Gomm, W, von Holt, K, Thome, F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol 73 (2016), 410–416.
28. Wijarnpreecha, K, Thongprayoon, C, Chesdachai, S, Panjawatanana, P, Ungprasert, P, Cheungpasitporn, W, Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis. Dig Dis Sci 62 (2017), 2821–2827.
29. Arora, P, Gupta, A, Golzy, M, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol, 17, 2016, 112.
30. Eikelboom, JW, Connolly, SJ, Bosch, J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377 (2017), 1319–1330.